Literature DB >> 31773448

Tumor immune microenvironment is associated with the growth of intracranial germinomas.

Masaaki Nishimoto1, Kentaro Ohara2, Dai Kamamoto1, Ryota Tamura1, Tomoru Miwa1, Kazunari Yoshida1, Hikaru Sasaki3.   

Abstract

INTRODUCTION: The role of immune checkpoint molecules and the tumor immune microenvironment in the development of intracranial germ cell tumors remains unclear.
METHODS: We investigated the expression of programed cell death-1 (PD-1), programed cell death ligand-1 (PD-L1), and tumor-infiltrating lymphocytes (TILs) in 8 patients who had intracranial germinomas with sufficient tumor tissue by immunohistochemistry, to analyze the associations between their clinical courses and radiological features. The 8 patients were categorized based on the duration between symptom onset and pathological diagnosis into the long-term onset (LTO) group (> 1 year of symptoms) and the short-term onset (STO) group (< 1 year of symptoms).
RESULTS: Three patients belonged to the LTO group and 5 patients to the STO group. Compared with STO tumors, LTO tumors were significantly associated with a lower ratio of PD-L1-positive tumor cells (p = 0.012), higher number of infiltrating CD3- and CD8-positive lymphocytes (p = 0.016, 0.003, respectively), and lower ratio of PD-1-positive cells per CD8-positive lymphocytes (p = 0.047). LTO germinomas were significantly smaller in size than STO tumors, not associated with hydrocephalus, and tended to be present in patients with older age at diagnosis and atypical tumor location.
CONCLUSIONS: Our data suggest that the tumor immune microenvironment, including PD-1/PD-L1 signaling, is associated with the growth of intracranial germinomas.

Entities:  

Keywords:  Germ cell tumor; Intracranial germinoma; PD-1; PD-L1; Tumor immune microenvironment; Tumor-infiltrating lymphocyte

Mesh:

Substances:

Year:  2019        PMID: 31773448     DOI: 10.1007/s11060-019-03355-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  42 in total

1.  Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion.

Authors:  Seunggu J Han; Brian J Ahn; James S Waldron; Isaac Yang; Shanna Fang; Courtney A Crane; Russell O Pieper; Andrew T Parsa
Journal:  Neuroreport       Date:  2009-12-09       Impact factor: 1.837

Review 2.  Immunomodulatory therapy for melanoma: ipilimumab and beyond.

Authors:  Margaret K Callahan; Michael A Postow; Jedd D Wolchok
Journal:  Clin Dermatol       Date:  2013 Mar-Apr       Impact factor: 3.541

3.  Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.

Authors:  Dai Kamamoto; Kentaro Ohara; Yohei Kitamura; Kazunari Yoshida; Yutaka Kawakami; Hikaru Sasaki
Journal:  J Neurooncol       Date:  2018-04-19       Impact factor: 4.130

Review 4.  Pediatric central nervous system germ cell tumors: a review.

Authors:  Maria E Echevarría; Jason Fangusaro; Stewart Goldman
Journal:  Oncologist       Date:  2008-06

5.  Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.

Authors:  Z Cierna; M Mego; V Miskovska; K Machalekova; M Chovanec; D Svetlovska; K Hainova; K Rejlekova; D Macak; S Spanik; D Ondrus; K Kajo; J Mardiak; P Babal
Journal:  Ann Oncol       Date:  2015-11-23       Impact factor: 32.976

Review 6.  Intracranial germ-cell tumors: natural history and pathogenesis.

Authors:  M T Jennings; R Gelman; F Hochberg
Journal:  J Neurosurg       Date:  1985-08       Impact factor: 5.115

Review 7.  PD-1 and PD-1 ligands: from discovery to clinical application.

Authors:  Taku Okazaki; Tasuku Honjo
Journal:  Int Immunol       Date:  2007-07-02       Impact factor: 4.823

8.  Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.

Authors:  Toyoaki Hida; Makoto Nishio; Naoyuki Nogami; Yuichiro Ohe; Hiroshi Nokihara; Hiroshi Sakai; Miyako Satouchi; Kazuhiko Nakagawa; Mitsuhiro Takenoyama; Hiroshi Isobe; Shiro Fujita; Hiroshi Tanaka; Koichi Minato; Toshiaki Takahashi; Makoto Maemondo; Koji Takeda; Hideo Saka; Koichi Goto; Shinji Atagi; Tomonori Hirashima; Naoki Sumiyoshi; Tomohide Tamura
Journal:  Cancer Sci       Date:  2017-04-26       Impact factor: 6.716

9.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

10.  PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes.

Authors:  Bin Liu; Yoshiki Arakawa; Ryuta Yokogawa; Shinya Tokunaga; Yukinori Terada; Daiki Murata; Yasuzumi Matsui; Ko-Ichi Fujimoto; Nobuyuki Fukui; Masahiro Tanji; Yohei Mineharu; Sachiko Minamiguchi; Susumu Miyamoto
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

View more
  2 in total

1.  The features of acute lymphocytic leukemia with intracranial germinoma in a patient with Li-Fraumeni syndrome: a case description.

Authors:  Yiwen Liang; Ke Wei; Weiguo Cao
Journal:  Quant Imaging Med Surg       Date:  2022-03

2.  Low tumor cell content predicts favorable prognosis in germinoma patients.

Authors:  Hirokazu Takami; Kaishi Satomi; Kohei Fukuoka; Shintaro Fukushima; Yuko Matsushita; Kai Yamasaki; Taishi Nakamura; Shota Tanaka; Akitake Mukasa; Nobuhito Saito; Tomonari Suzuki; Takaaki Yanagisawa; Hideo Nakamura; Kazuhiko Sugiyama; Kaoru Tamura; Taketoshi Maehara; Mitsutoshi Nakada; Masahiro Nonaka; Akio Asai; Kiyotaka Yokogami; Hideo Takeshima; Toshihiko Iuchi; Yonehiro Kanemura; Keiichi Kobayashi; Motoo Nagane; Kazuhiko Kurozumi; Koji Yoshimoto; Masahide Matsuda; Akira Matsumura; Yuichi Hirose; Tsutomu Tokuyama; Toshihiro Kumabe; Yoshitaka Narita; Soichiro Shibui; Yoichi Nakazato; Ryo Nishikawa; Masao Matsutani; Koichi Ichimura
Journal:  Neurooncol Adv       Date:  2021-08-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.